Corticosteroids, in particular dexamethasone, are an effective anti-emetic agent in many situations including oncology, paediatric and adult surgical patients [1] [2] [3] . Evidence suggests that dexamethasone may have an additive anti-emetic effect when combined with other anti-emetic agents 1, 2 . In addition to anti-emetic activity, dexamethasone may also reduce analgesic requirement after ear surgery 4 , airway swelling after orthognathic surgery 5 and risk of atrial fibrillation after on-pump cardiac surgery 6 .
Although dexamethasone is widely used as an adjunct in many perioperative settings, its risks have not been thoroughly assessed. The side-effects of dexamethasone may include an increased risk of hyperglycaemia 6 , bleeding 7 , perineal pain 8 , resistance to muscle relaxants 9 , impaired wound healing 10, 11 and possibly infection 12 . In this issue of Anaesthesia and Intensive Care we have three interesting observational studies on potential side-effects of perioperative dexamethasone [13] [14] [15] , two of them suggesting that a single dose of dexamethasone may not be completely innocuous 13, 15 .
The two observational studies on risk of dexamethasone for inducing perioperative infections have some strength in challenging the dogma that a single dose of dexamethasone is harmless. First, both observational studies have a reasonable sample size (n=235 and n=439) and many potential confounders, including the types of operative procedure, comorbidity and use of perioperative antibiotics were considered. Second, the duration of followup for infection was not limited to before hospital discharge. Despite these strengths and the fact that the characteristics of the study patients were also very similar, their conclusions on the risk of infections after a single dose of intraoperative dexamethasone were remarkably different.
How should we interpret the contradictory findings of these two studies? First, both studies used a wide range of definitions of the presence of an infection and a positive microbiological culture was not a mandatory criterion. This could have misclassified some 'controls' as 'cases' and, in a case control study, we have no way of assessing how this problem would have affected the relationship between the risk of infection (the outcome) and the use of dexamethasone (the exposure) 16 .
Second, a cohort study is, in general, more robust than a case control study. Criticisms of the case control study published in this issue of Anaesthesia and Intensive Care may be their inclusion of infections that occurred after the second or third operative procedure as 'cases', including age and gender as covariates in the multivariate model when they were already used to match the 'cases' and 'controls', and a slight imbalance in the types of operative procedure between the 'cases' and 'controls', despite the use of matching. Although the authors have excluded procedures that dealt with infective complications, there was still a significant imbalance in the number of procedures performed on the 'cases' and 'controls'. Over 90% of the 'control' patients had only one operative procedure compared to only 71% of the 'cases'. It is not surprising that the 'cases' would have a higher risk of infection if they had more operative procedures, even though these procedures were not performed for infective complications. When the matched variables are analysed as covariates in a conditional logistic regression, it is important to stratify the matched variables so that each stratum of the matched variable will have its own intercept in the regression equation. As such, the age of the patient should preferably be stratified in the analysis of this case control study. As for the mismatch in the types of procedure between the 'cases' and 'controls', the 'control' group had indeed a higher proportion of patients who had orthopaedic surgery (26.2 vs 19%), breast surgery (14.5 vs 11.1%) and a lower proportion of patients with colonic surgery (11 vs 15.9%) when compared to the 'cases'. This could have created an apparent association between dexamethasone and infection because of residual confounding 17 . Finally, meta-analyses on randomised controlled studies on the use of corticosteroids in adult cardiac surgery did not suggest an increased risk of infection 6 .
The study by Cowie et al on effect of dexamethasone on serum cortisol concentrations is also interesting 15 . This study showed that a single 8 mg dose of intra-venous dexamethasone could suppress cortisol secretion and induce mild hyperglycaemia up to 24 hours after an elective laparoscopic cholecytectomy 15 . First, this study reminded us that dexamethasone is indeed a very potent corticosteroid. The glucocorticoid effect of dexamethasone is about 25 times more potent than hydrocortisone 6 ; an 8 mg of dexamethasone will be equivalent to the potency of 200 mg of hydrocortisone. Because the normal daily cortisol secretion in a healthy adult is only in the range of 30 to 50 mg, an 8 mg dose of dexamethasone is thus potent enough to inhibit pituitary corticotropin secretion and the serum cortisol concentrations. The more important question that remains unanswered is whether the adrenal glands will be suppressed for a prolonged period of time by a single dose of perioperative dexamethasone. If a single dose of dexamethasone is capable of suppressing adrenal responses to a corticotropin stimulation test (the short Synacthen test), similar to the effect of etomidate, the clinical implication of using dexamethasone as a routine anti-emetic agent will be profound.
So how should we proceed from here? First, although the current evidence is insufficient to prove that dexamethasone will increase the risk of postoperative infection or adrenal suppression, it does not mean that we have sufficient evidence to state that a single dose of dexamethasone is harmless in the perioperative setting. Experimental and clinical data suggest that we should be cautious, especially when an increased risk of poor wound healing and infection after a surgical procedure is associated with significant mortality and morbidity.
The obvious examples are bowel resection surgery and tonsillectomy 7, 10, 11 . Second, we should assess the safety and effectiveness of dexamethasone as an antiemetic agent by an adequately powered randomised controlled trial. If the baseline risk of infection in the control group is 8%, a sample size of more than 6000 patients will be needed to exclude a 2% increase in absolute risk of infection, assuming the power of the trial is 80%. The issues of cost-effectiveness and adrenal gland suppression should also be addressed. The results of two ongoing randomised controlled trials, the European Dexamethasone for Cardiac Surgery trial and the Canadian steroids in cardiac surgery study may give us more information on risks and benefits of high-dose corticosteroids in cardiac surgery. With the success of our previous multicentre trials in Australia, Australian anaesthetists are in the best position to conduct a definitive phase IV trial on cost-effectiveness of low-dose dexamethasone as an anti-emetic agent in non-cardiac surgery. Until the results of this definitive trial are available, the risks and benefits of using dexamethasone as antiemetic prophylaxis should be carefully considered, especially for patients undergoing bowel resection surgery and tonsillectomy.
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